<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zettlitz KA</submitter><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIH HHS</funding><pagination>489-500</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6580847</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>46(2)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Metabolic imaging using [&lt;sup>18&lt;/sup>F]FDG is the current standard for clinical PET; however, some malignancies (e.g., indolent lymphomas) show low avidity for FDG. The majority of B cell lymphomas express CD20, making it a valuable target both for antibody-based therapy and imaging. We previously developed PET tracers based on the humanised anti-CD20 antibody obinutuzumab (GA101). Preclinical studies showed that the smallest bivalent fragment, the cys-diabody (GAcDb, 54.5 kDa) with a peak uptake at 1-2 h post-injection and a biological half-life of 2-5 h, is compatible with short-lived positron emitters such as fluorine-18 (&lt;sup>18&lt;/sup>F, t&lt;sub>1/2&lt;/sub> 110 min), enabling same-day imaging.&lt;h4>Methods&lt;/h4>GAcDb was radiolabeled using amine-reactive N-succinimidyl 4-[&lt;sup</pubmed_abstract><journal>European journal of nuclear medicine and molecular imaging</journal><pubmed_title>&lt;sup>18&lt;/sup>F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.</pubmed_title><pmcid>PMC6580847</pmcid><funding_grant_id>CA149254</funding_grant_id><funding_grant_id>P30 CA016042</funding_grant_id><funding_grant_id>R21 CA212718</funding_grant_id><funding_grant_id>CA212718</funding_grant_id><funding_grant_id>R01 CA149254</funding_grant_id><funding_grant_id>R01 CA174294</funding_grant_id><funding_grant_id>CA016042</funding_grant_id><pubmed_authors>Wu AM</pubmed_authors><pubmed_authors>Tsai WK</pubmed_authors><pubmed_authors>Tavare R</pubmed_authors><pubmed_authors>Zettlitz KA</pubmed_authors><pubmed_authors>van Dam RM</pubmed_authors><pubmed_authors>Yamada RE</pubmed_authors><pubmed_authors>Timmerman JM</pubmed_authors><pubmed_authors>Ha NS</pubmed_authors><pubmed_authors>Collins J</pubmed_authors></additional><is_claimable>false</is_claimable><name>&lt;sup>18&lt;/sup>F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.</name><description>&lt;h4>Purpose&lt;/h4>Metabolic imaging using [&lt;sup>18&lt;/sup>F]FDG is the current standard for clinical PET; however, some malignancies (e.g., indolent lymphomas) show low avidity for FDG. The majority of B cell lymphomas express CD20, making it a valuable target both for antibody-based therapy and imaging. We previously developed PET tracers based on the humanised anti-CD20 antibody obinutuzumab (GA101). Preclinical studies showed that the smallest bivalent fragment, the cys-diabody (GAcDb, 54.5 kDa) with a peak uptake at 1-2 h post-injection and a biological half-life of 2-5 h, is compatible with short-lived positron emitters such as fluorine-18 (&lt;sup>18&lt;/sup>F, t&lt;sub>1/2&lt;/sub> 110 min), enabling same-day imaging.&lt;h4>Methods&lt;/h4>GAcDb was radiolabeled using amine-reactive N-succinimidyl 4-[&lt;sup</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Feb</publication><modification>2025-04-22T14:13:22.353Z</modification><creation>2020-10-29T11:02:32Z</creation></dates><accession>S-EPMC6580847</accession><cross_references><pubmed>30456475</pubmed><doi>10.1007/s00259-018-4214-x</doi></cross_references></HashMap>